(ARWR) Arrowhead Pharmaceuticals - Ratings and Ratios
Arrowhead, siRNA, Therapy, Liver, Disease
ARWR EPS (Earnings per Share)
ARWR Revenue
Description: ARWR Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) is a biotechnology company listed on the NASDAQ exchange, operating in the biotechnology sub-industry. The companys stock is classified as a common stock, and its country of origin is the United States.
To evaluate the companys financial health, we can look at its market capitalization, which stands at approximately $2.28 billion. The stocks price-to-earnings (P/E) ratio is not available due to negative earnings, while the forward P/E ratio is around 111.11, indicating high growth expectations. The return on equity (RoE) is -46.00%, suggesting significant losses. Key economic drivers for ARWR include the success of its pipeline products, particularly those in clinical trials, and the overall demand for biotechnology innovations.
From a trading perspective, the stocks price is currently at $16.06, with various moving averages (SMA20, SMA50, SMA200) indicating potential support and resistance levels. The average true range (ATR) is 0.80, representing a 5.01% daily price movement. The beta of 0.952 suggests that the stocks price movements are relatively in line with the overall market. To assess the stocks potential, we can monitor key performance indicators (KPIs) such as revenue growth, R&D expenses as a percentage of revenue, and cash burn rate.
Investors should also consider the companys cash position, burn rate, and funding requirements to support its research and development activities. The biotechnology industry is highly competitive, and ARWRs success will depend on its ability to bring innovative products to market, obtain regulatory approvals, and navigate the complex landscape of intellectual property and partnerships.
ARWR Stock Overview
| Market Cap in USD | 3,871m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1993-06-16 |
ARWR Stock Ratings
| Growth Rating | -23.4% |
| Fundamental | 26.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 22.8% |
| Analyst Rating | 4.13 of 5 |
ARWR Dividends
Currently no dividends paidARWR Growth Ratios
| Growth Correlation 3m | 80.7% |
| Growth Correlation 12m | -29.1% |
| Growth Correlation 5y | -93.1% |
| CAGR 5y | -3.60% |
| CAGR/Max DD 3y | -0.05 |
| CAGR/Mean DD 3y | -0.10 |
| Sharpe Ratio 12m | 0.62 |
| Alpha | 0.26 |
| Beta | 0.286 |
| Volatility | 62.61% |
| Current Volume | 1873.7k |
| Average Volume 20d | 2477k |
| Stop Loss | 27.2 (-6.6%) |
| Signal | -0.60 |
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-148.4m TTM) > 0 and > 6% of Revenue (6% = 35.8m TTM) |
| FCFTA -0.44 (>2.0%) and ΔFCFTA -6.36pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 126.1% (prev 1798 %; Δ -1672 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.02 (>3.0%) and CFO 21.8m > Net Income -148.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 4.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (139.0m) change vs 12m ago 11.95% (target <= -2.0% for YES) |
| Gross Margin 94.78% (prev 11.29%; Δ 83.49pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 52.69% (prev 2.22%; Δ 50.47pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -1.12 (EBITDA TTM -69.6m / Interest Expense TTM 82.3m) >= 6 (WARN >= 3) |
Altman Z'' -3.28
| (A) 0.54 = (Total Current Assets 946.9m - Total Current Liabilities 194.5m) / Total Assets 1.38b |
| (B) -1.16 = Retained Earnings (Balance) -1.60b / Total Assets 1.38b |
| warn (B) unusual magnitude: -1.16 — check mapping/units |
| (C) -0.08 = EBIT TTM -92.1m / Avg Total Assets 1.13b |
| (D) -2.40 = Book Value of Equity -1.60b / Total Liabilities 666.3m |
| Total Rating: -3.28 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 26.71
| 1. Piotroski 2.50pt = -2.50 |
| 2. FCF Yield -19.01% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.40 = 2.42 |
| 5. Debt/Ebitda -2.98 = -2.50 |
| 6. ROIC - WACC (= -20.53)% = -12.50 |
| 7. RoE -41.19% = -2.50 |
| 8. Rev. Trend -12.25% = -0.92 |
| 9. EPS Trend 4.04% = 0.20 |
What is the price of ARWR shares?
Over the past week, the price has changed by +0.83%, over one month by +46.31%, over three months by +87.94% and over the past year by +45.58%.
Is Arrowhead Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ARWR is around 28.44 USD . This means that ARWR is currently overvalued and has a potential downside of -2.37%.
Is ARWR a buy, sell or hold?
- Strong Buy: 7
- Buy: 3
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ARWR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 44.1 | 51.3% |
| Analysts Target Price | 44.1 | 51.3% |
| ValueRay Target Price | 31.3 | 7.6% |
Last update: 2025-09-05 04:33
ARWR Fundamental Data Overview
CCE Cash And Equivalents = 900.4m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 111.1111
P/S = 6.7563
P/B = 7.3587
P/EG = -1.32
Beta = 1.01
Revenue TTM = 596.6m USD
EBIT TTM = -92.1m USD
EBITDA TTM = -69.6m USD
Long Term Debt = 200.3m USD (from longTermDebt, last quarter)
Short Term Debt = 7.01m USD (from shortTermDebt, last quarter)
Debt = 207.3m USD (Calculated: Short Term 7.01m + Long Term 200.3m)
Net Debt = -17.1m USD (from netDebt column, last quarter)
Enterprise Value = 3.18b USD (3.87b + Debt 207.3m - CCE 900.4m)
Interest Coverage Ratio = -1.12 (Ebit TTM -92.1m / Interest Expense TTM 82.3m)
FCF Yield = -19.01% (FCF TTM -604.3m / Enterprise Value 3.18b)
FCF Margin = -101.3% (FCF TTM -604.3m / Revenue TTM 596.6m)
Net Margin = -24.88% (Net Income TTM -148.4m / Revenue TTM 596.6m)
Gross Margin = 94.78% ((Revenue TTM 596.6m - Cost of Revenue TTM 31.1m) / Revenue TTM)
Tobins Q-Ratio = -1.99 (set to none) (Enterprise Value 3.18b / Book Value Of Equity -1.60b)
Interest Expense / Debt = 11.76% (Interest Expense 24.4m / Debt 207.3m)
Taxrate = 21.0% (US default)
NOPAT = -92.1m (EBIT -92.1m, no tax applied on loss)
Current Ratio = 4.87 (Total Current Assets 946.9m / Total Current Liabilities 194.5m)
Debt / Equity = 0.40 (Debt 207.3m / last Quarter total Stockholder Equity 519.8m)
Debt / EBITDA = -2.98 (Net Debt -17.1m / EBITDA -69.6m)
Debt / FCF = -0.34 (Debt 207.3m / FCF TTM -604.3m)
Total Stockholder Equity = 360.3m (last 4 quarters mean)
RoA = -10.75% (Net Income -148.4m, Total Assets 1.38b )
RoE = -41.19% (Net Income TTM -148.4m / Total Stockholder Equity 360.3m)
RoCE = -16.43% (Ebit -92.1m / (Equity 360.3m + L.T.Debt 200.3m))
RoIC = -13.35% (NOPAT -92.1m / Invested Capital 690.1m)
WACC = 7.18% (E(3.87b)/V(4.08b) * Re(7.07%)) + (D(207.3m)/V(4.08b) * Rd(11.76%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 84.85 | Cagr: 2.52%
Discount Rate = 7.07% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -604.3m)
EPS Correlation: 4.04 | EPS CAGR: -31.69% | SUE: -0.30 | # QB: 0
Revenue Correlation: -12.25 | Revenue CAGR: -4.57% | SUE: N/A | # QB: None
Additional Sources for ARWR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle